VALN

5.1603.82%
JR

James R. Sulat

Independent Vice Chairman

Mr. James R. Sulat, also known as Jim, MBA, serves as Vice Chairman at Valneva SE. He served as Independent Director at Mallinckrodt plc since June 16, 2022 until November 2023. He served as the Vice Chairman of the Supervisory Board at Valneva SE until December 20, 2023 and serves as Director since December 20, 2023. Mr. Sulat had been an Independent Director of Exicure, Inc. since January 2, 2021 until December 30, 2022. He served as a Vice President of Finance and MIS at D.B. Hess, Inc. Mr. Sulat served as the Chief Executive Officer and Chief Financial Officer of Maxygen Inc. from October 1, 2009 to June 30, 2013 and served as its Principal Accounting Officer until June 30, 2013. He has experience in advising and leading biopharmaceutical companies, including serving in the roles of President, Chief Executive Officer and Chief Financial Officer at various companies. He served as a Consultant of Maxygen, Inc. since June 30, 2013. He served as an Interim Chief Financial Officer for Moore Wallace Inc. since February 9, 2004. Mr. Sulat served as Senior Executive Vice President of Moore Wallace Inc. from April 2003 to February 2004. He served as the President and Chief Executive Officer of Memory Pharmaceuticals Corp. from May 17, 2005 to February 2008 and served as its Principal Financial Officer from February 2008 to September 2008. He served as an Interim Chief Financial Officer and Senior Executive Vice President of R.R. Donnelley & Sons Co. from March 2, 2004 to May 2004. He served as Chief Financial Officer of R.R. Donnelley until May 2004. He served as Vice President and Chief Financial Officer of Chiron, Corp. from April 1998 to April 21, 2003. He served as Chief Financial Officer of Stanford Health Services from 1993 to March 1998. In November 1997, Stanford Health Services merged with the hospital facilities of the University of California, San Francisco and he served as the Treasurer of the merged entity, UCSF Stanford Health Care. He managed the Strategic Planning and Merger Processes for the creation of Stanford Health Services, its combination with Lucille Packard Children's Hospital and the creation of UCSF Stanford Health Care. He served as Chairman of Momenta Pharmaceuticals Inc. since December 2008 until June 2018. He served as Director of Ariat International, Inc. He had been Member of the Supervisory Board at Valneva SE since March 7, 2013 until December 20, 2023. He had been an Independent Director at Arch Therapeutics, Inc since August 19, 2015 until December 31, 2021. He has been a Member of Board of Managers of Perseid Therapeutics LLC since September 2009. He had been an Independent Director of AMAG Pharmaceuticals, Inc. since April 16, 2014 until November 16, 2020. He served as Director at Tolero Pharmaceuticals, Inc. Mr. Sulat served as the Chief Financial Officer in several different large and mid-sized public companies. He served as a Director of General Surgical Innovations, Inc. since January 1997. He served as a Director of VANS, Inc since October 1994. Mr. Sulat had been a Director at Momenta Pharmaceuticals Inc. since June 5, 2008 until July 22, 2019. He served as a Director of Codexis Inc. since 2009. He served as a Director of diaDexus, Inc. since January 2015. He served as a Director at Maxygen, Inc., from October 2003 to June 30, 2013 and Memory Pharmaceuticals Corp. since May 17, 2005 until 2008. He served as Member of Supervisory Board at Intercell AG since September 2004. Mr. Sulat holds a B.S. degree in Administrative Sciences from Yale University and M.S. in Health Services Administration and M.B.A. in Health Services Administration from Stanford University Graduate School of Business.

Positions